Product Line and Significant Customer Information

3 Months Ended

Mar. 31, 2012

Segment Reporting [Abstract]

Product Line and Significant Customer Information

Product Line and Significant Customer Information

The Company currently operates in one business segment: the development, manufacturing, marketing, sales and support of molecular diagnostic products primarily to diagnose human diseases, screen donated human blood and ensure transplant compatibility.

Product sales by product line for the three month periods ended March 31, 2012 and 2011 were as follows (in thousands):

	Three Months Ended March 31,
	2012				2011
	$		%		$		%
Clinical diagnostics	$	94,919	63	%	$	88,290	64	%
Blood screening	52,543		35	%	46,705		34	%
Research products and services	2,655		2	%	3,117		2	%
Total product sales	$	150,117	100	%	$	138,112	100	%

During the three month periods ended March 31, 2012 and 2011, 36% and 35%, respectively, of the Company’s total revenues were from Novartis. No other customer accounted for more than 10% of the Company’s revenues during the three month periods ended March 31, 2012 and 2011.